Cambridge Epigenetix

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw.

CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health.

Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease.

A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Cambridge Epigenetix headquartered in Europe, operates in the Biotechnology, Health Care, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $12.4B in funding across 80 round(s). With a team of 11-50 employees, Cambridge Epigenetix is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cambridge Epigenetix, raised $5.5M. Discover more about their projects, partnerships, and impact on our platform.